Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 87 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in... April 11, 2022 EMA Recommends Extension of Indications for Venetoclax May 14, 2021 Cancer in My Community: Addressing Health Disparities in Brazil July 18, 2023 Haematologic Toxicity Not Increased with Immunochemotherapy Combinations Over Chemotherapy Treatment for... December 9, 2020 Load more HOT NEWS New on NCI’s Websites for July 2021 Survey Shows Oncologists Underestimate How Many Cancer Patients Use Alternative Therapies Mother Of 6 With ‘Open-Door Policy’ Packs 100 Lunches For Hungry... Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with...
